NCT05765955View on ClinicalTrials.gov

Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

July 22, 2022

Primary Completion Date

December 14, 2022

Study Completion Date

December 16, 2022

Conditions

Influenza, Human

Interventions

DRUG

POLB 001

Investigational Medicinal Product

DRUG

Placebo

Matching Placebo

Trial Locations (1)

2333 CL

Centre for Human Drug Research, Leiden

Sponsors

Lead Sponsor

Poolbeg Pharma plc

All Listed Sponsors

lead

Poolbeg Pharma plc

INDUSTRY

NCT05765955 - Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses | Biotech Hunter | Biotech Hunter